AAN 2026: Tavapadon helps delay levodopa start in early Parkinson’s
WHY IT MATTERS
If approved, tavapadon could allow people with early Parkinson's to delay levodopa therapy, potentially postponing side effects that come with long-term use of this standard medication.
A new experimental drug called tavapadon from AbbVie helped people with early Parkinson's disease delay or avoid starting levodopa, which is the standard treatment for this condition. In a completed Phase 3 trial called TEMPO-4, most people taking tavapadon long-term did not need to start levodopa, and those already taking it didn't need to increase their dose. This suggests tavapadon could be a helpful new option for managing early Parkinson's symptoms.
While on long-term treatment with Abbvie’s experimental oral drug tavapadon, most people with early Parkinson’s disease did not need to start levodopa — the mainstay therapy for the progressive condition — and most individuals already taking levodopa didn’t need to increase their dose. That’s according to new results from the now-completed Phase 3 TEMPO-4 (NCT04760769) […] The post AAN 2026: Tavapadon helps delay levodopa start in early Parkinson’s appeared first on Parkinson's News T
ASK YOUR DOCTOR
Ask your neurologist at your next appointment whether tavapadon might be appropriate for you once it becomes available, especially if you're in early-stage Parkinson's disease.